
Pharma Pulse 12/10/24: Quantifying Benefits of AI-Powered Patient Adherence Programs, Protecting High-Risk Adults from Severe RSV & more
The latest news for pharma industry insiders.
In this part of his Pharmaceutical Executive video interview, Bill Grambley, CEO of AllazoHealth, identifies which metrics and KPIs can be used to measure the effectiveness of AI-powered patient engagement and adherence programs.
Jeffery A. Goad, PharmD, MPH, President of the National Foundation for Infectious Diseases (NFID), discussed the significant severity of RSV in older adults in an interview with Pharmacy Times®. Goad shared the updated Advisory Committee on Immunization Practices (ACIP) recommendations that simplify vaccination eligibility, and the high efficacy of the available RSV vaccines in preventing severe disease. He also emphasized the importance of comprehensive respiratory illness prevention strategies, including vaccination against RSV as well as other respiratory pathogens like influenza and COVID-19.
A clash among lawyers from Elon Musk’s X Corp., Alex Jones’ Infowars, and The Onion would normally be enough to pack a courtroom.
Acadia Pharmaceuticals Inc. announced that Thomas Andrew Garner has been appointed Chief Commercial Officer, effective today. Mr. Garner will spearhead Acadia's commercial strategy and operations, driving the Company's plans for sustained growth and expansion of its product portfolio and pipeline across U.S. and international markets. Mr. Garner will report to Catherine Owen Adams, Acadia’s CEO, and serve on the executive leadership team.
Maybe this discussion piques the interest of industry supply chain pro's who have thought about RFID at the packaging line in the past, and may delve into what's possible today.
Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor
Newsletter
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.

